The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay is intended for the qualitative determination of benzoylecgonine (a cocaine metabolite) in human urine at a cutoff value of 150 ng/mL. Rx only. This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or Liquid Chromatograph/Mass Spectrometry (GC/MS or LC/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.
Device Story
Pointe Scientific Cocaine Metabolite Enzyme Immunoassay is an in vitro diagnostic reagent kit for qualitative detection of benzoylecgonine in human urine. Device utilizes competitive enzyme immunoassay principle; drug in sample competes with enzyme-labeled drug (G6PDH) for fixed antibody binding sites. In absence of drug, enzyme-labeled conjugate binds antibody, inhibiting enzyme activity. Presence of drug displaces conjugate, allowing enzyme to convert NAD to NADH, producing absorbance change measured spectrophotometrically at 340 nm. Assay is performed on BS-480 or BA-800 Chemistry Analyzers in clinical laboratory settings by trained personnel. Results provide preliminary screening; positive results require confirmation via GC/MS or LC/MS. Clinical decision-making must incorporate professional judgment and confirmatory testing. Benefits include rapid, automated screening for cocaine metabolite presence in urine samples.
Clinical Evidence
Bench testing only. Precision evaluated over 20 days on BS-480 and BA-800M analyzers using spiked urine samples. Method comparison performed on 114 clinical urine samples against LC/MS reference method. No clinical studies (sensitivity/specificity in patient populations) were required or performed.
Indicated for qualitative detection of benzoylecgonine in human urine at 150 ng/mL cutoff. For prescription use only. Requires confirmatory testing via GC/MS or LC/MS.
Regulatory Classification
Identification
A cocaine and cocaine metabolite test system is a device intended to measure cocaine and a cocaine metabolite (benzoylecgonine) in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of cocaine use or overdose.
Special Controls
*Classification.* Class II (special controls). A cocaine and cocaine metabolite test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Predicate Devices
Cocaine Metabolite Enzyme Immunoassay (k113139)
Submission Summary (Full Text)
{0}
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
ASSAY ONLY
## I Background Information:
A 510(k) Number
k191638
B Applicant
MedTest Dx
C Proprietary and Established Names
Pointe scientific cocaine metabolite enzyme immunoassay
D Regulatory Information
| Product Code(s) | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| DIO | Class II | 21 CFR 862.3250 - Cocaine And Cocaine Metabolite Test System | TX - Clinical Toxicology |
## II Submission/Device Overview:
A Purpose for Submission:
New Device
B Measurand:
Benzoylecgonine
C Type of Test:
Immunoassay
k191638 - Page 1 of 9
{1}
k191638 - Page 2 of 9
## III Intended Use/Indications for Use:
### A Intended Use(s):
See Indications for Use below.
### B Indication(s) for Use:
The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay is intended for the qualitative determination of benzoylecgonine (a cocaine metabolite) in human urine at a cutoff value of 150 ng/mL. Rx only.
This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or Liquid Chromatograph/Mass Spectrometry (GC/MS or LC/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.
### C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
### D Special Instrument Requirements:
- BS-480 Chemistry Analyzer
- BA-800 Chemistry Analyzer
## IV Device/System Characteristics:
### A Device Description:
The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay consists of ready-to-use liquid reagents:
- Reagent 1 contains a mouse monoclonal anti-benzoylecgonine antibody, glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide (NAD), stabilizers and sodium azide (0.09%) as a preservative.
- Reagent 2 contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with benzoylecgonine in buffer with sodium azide (0.09%) as a preservative.
The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay has a cutoff of 150 ng/mL benzoylecgonine.
### B Principle of Operation:
{2}
The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, benzoylecgonine-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. On the other hand, when drug is present in the sample, antibody binds to the free drug; the unbound benzoylecgonine-labeled G6PDH then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at a 340 nm primary wavelength.
k191638 - Page 3 of 9
V Substantial Equivalence Information:
A Predicate Device Name(s):
Cocaine Metabolite Enzyme Immunoassay
B Predicate 510(k) Number(s):
k113139
C Comparison with Predicate(s):
| Device & Predicate Device(s): | k191638 | k113139 |
| --- | --- | --- |
| Device Trade Name | Pointe Scientific Cocaine Metabolite Enzyme Immunoassay | Cocaine Metabolite Enzyme Immunoassay |
| General Device Characteristic Similarities | | |
| Intended Use/Indications For Use | To be used for the determination of benzoylecgonine in human urine.
This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or Liquid Chromatograph/Mass Spectrometry (GC/MS or LC/MS) is the preferred confirmatory method. | Same |
| Contents | The assay consists of ready-to-use liquid reagents. Reagent 1 contains a mouse | Same |
{3}
k191638 - Page 4 of 9
| Device & Predicate Device(s): | k191638 | k113139 |
| --- | --- | --- |
| | monoclonal anti-benzoylecgonine antibody, glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide (NAD), stabilizers and sodium azide (0.09%) as a preservative. Reagent 2 contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with benzoylecgonine in buffer with sodium azide (0.09%) as a preservative | |
| Analyte | Benzoylecgonine | Same |
| Cutoff | 150 ng/mL | Same |
| Matrix | Urine | Same |
| Controls | 2 levels (112.5 ng/mL, 187.5 ng/mL) | Same |
| Storage | 2-8°C until expiration date | Same |
| General Device Characteristic Differences | | |
| Calibrators | 2 Levels (0 ng/mL, 150 ng/mL) | 5 Levels (0, 75, 150, 300, 1000 ng/mL) |
VI Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
Precision was determined by spiking benzoylecgonine into drug free urine at various concentrations (zero, -75%, -50%, -25%, at the cutoff, 125%, 150%, 175% and 200% of the cutoff). Concentrations were confirmed by LC/MS. Testing for both the with-in run and between-run studies were performed by testing each sample in 2 replicates, with two runs per day, for 20 days, on both the BS-480 Chemistry Analyzer and the BS-800M Chemistry Analyzer. The qualitative results are presented below as Positive/Negative.
BS-480 Chemistry Analyzer:
| | Within Run | | Between Run | |
| --- | --- | --- | --- | --- |
| Sample concentration (ng/mL) | No. Observations | # Neg/#Pos | No. Observations | # Neg/#Pos |
{4}
k191638 - Page 5 of 9
| 0 (negative) | 20 | 20/0 | 80 | 80/0 |
| --- | --- | --- | --- | --- |
| 37.5 (-75% c/o) | 20 | 20/0 | 80 | 80/0 |
| 75 (-50% c/o) | 20 | 20/0 | 80 | 80/0 |
| 112.5 (-25% c/o) | 20 | 20/0 | 80 | 80/0 |
| 150 (cutoff) | 20 | 19/1 | 80 | 68/12 |
| 187.5 (+25% c/o) | 20 | 0/20 | 80 | 0/80 |
| 225 (+50% c/o) | 20 | 0/20 | 80 | 0/80 |
| 262.5 (+75% c/o) | 20 | 0/20 | 80 | 0/80 |
| 300 (+100% c/o) | 20 | 0/20 | 80 | 0/80 |
BA-800M Chemistry Analyzer:
| | Within Run | | Between Run | |
| --- | --- | --- | --- | --- |
| Sample concentration (ng/mL) | No. Observations | # Neg/#Pos | No. Observations | # Neg/#Pos |
| 0 (negative) | 20 | 20/0 | 80 | 80/0 |
| 37.5 (-75% c/o) | 20 | 20/0 | 80 | 80/0 |
| 75 (-50% c/o) | 20 | 20/0 | 80 | 80/0 |
| 112.5 (-25% c/o) | 20 | 20/0 | 80 | 80/0 |
| 150 (cutoff) | 20 | 7/13 | 80 | 41/39 |
| 187.5 (+25% c/o) | 20 | 0/20 | 80 | 0/80 |
| 225 (+50% c/o) | 20 | 0/20 | 80 | 0/80 |
| 262.5 (+75% c/o) | 20 | 0/20 | 80 | 0/80 |
| 300 (+100% c/o) | 20 | 0/20 | 80 | 0/80 |
2. Linearity:
Not applicable.
3. Analytical Specificity/Interference:
The following endogenous compounds were added into drug-free urine, urine sample spiked with benzoylecgonine to 75% of cutoff value and urine spiked with benzoylecgonine to 125% of cutoff value. The substances listed in the table below were determined not to interfere at the concentration shown.
Results were identical for both the BS-480 Chemistry Analyzer and the BS-800M Chemistry Analyzer.
| Interfering Substances | Spiked [ ] (mg/dL) | Qualitative Result | | |
| --- | --- | --- | --- | --- |
| | | 0 ng/mL (Pos/Neg) | 112.5 ng/mL Control (Pos/Neg) | 187.5 ng/mL Control (Pos/Neg) |
| Acetaminophen | 10 | Neg | Neg | Pos |
{5}
To test for possible positive and/or negative interference from pH, urine samples having pH from 3, 4, 5, 6, 7, 8, 9, 10 and 11 were used. Each of these samples were divided into two aliquots for each drug and spiked with benzoylecgonine to 75% of the cutoff and 125% of the cutoff. No positive or negative interference due to pH was observed on either the BS-480 Chemistry Analyzer or the BS-800M Chemistry Analyzer.
To test for possible positive and/or negative interference from specific gravity, urine samples having specific gravity ranging from 1.009 g/mL to 1.031 g/mL were used. Each of these samples were divided into three aliquots and two were spiked with benzoylecgonine to 75% of the cutoff and 125% of the cutoff, the third was not spiked. No positive or negative interference due to specific gravity was observed on either the BS-480 Chemistry Analyzer or the BS-800M Chemistry Analyzer.
## Cross Reactivity
Cross-reactivity was established by spiking various concentrations of structurally related and unrelated compounds into drug-free urine.
The following tables summarize approximate the quantity of each compound that is equivalent in assay reactivity to the 150 ng/mL benzoylecgonine cutoff. Results are expressed as a minimum concentration of metabolite or compound required to produce a response approximately equivalent to the cutoff concentration of the assay or the maximal concentration of the compound tested that gave a response with cross-reactivity below the cutoff calibrator. The percent cross-reactivity of those compounds are presented below.
Structurally Related Cocaine Compound:
| Cross-reactant | Target Concentration (ng/mL) | % Cross Reactivity |
| --- | --- | --- |
| Benzoylecgonine | 150 | 100 % |
| Cocaethylene | 4,000 | 4.58 % |
| Cocaine (BS-480) | 25,000 | 0.62% |
k191638 - Page 6 of 9
{6}
Structurally Unrelated Pharmacological Compounds
| Cross-reactant | Target Concentration (ng/mL) | % Cross Reactivity |
| --- | --- | --- |
| Acetaminophen | 500,000 | 0.00 % |
| Acetylsalicylic Acid | 500,000 | 0.00 % |
| Amobarbital | 500,000 | 0.00 % |
| Amoxicillin | 500,000 | 0.00 % |
| Amphetamine | 500,000 | 0.00 % |
| Bupropion | 500,000 | 0.00 % |
| Captopril | 500,000 | 0.00 % |
| Caffeine | 500,000 | 0.00 % |
| Chlordiazepoxide | 500,000 | 0.00 % |
| Chlorpheniramine | 500,000 | 0.00 % |
| Chlorpomazine | 500,000 | 0.00 % |
| Codeine | 500,000 | 0.00 % |
| Dextromethorphan | 500,000 | 0.00 % |
| Diazepam | 500,000 | 0.00 % |
| Digoxin | 500,000 | 0.00 % |
| Enalapril | 500,000 | 0.00 % |
| Fluoxetine | 100,000 | 0.01 % |
| Glyburide | 500,000 | 0.00 % |
| Ibuprofen | 500,000 | 0.00 % |
| Lidocaine | 500,000 | 0.00 % |
| Meperidine | 500,000 | 0.00 % |
| Methadone | 100,000 | 0.01 % |
| Methamphetamine | 500,000 | 0.00 % |
| Methaqualone | 500,000 | 0.00 % |
| Morphine | 500,000 | 0.00 % |
| Nicodine | 500,000 | 0.00 % |
| Nifedipine | 100,000 | 0.00 % |
| Oxazepam | 100,000 | 0.00 % |
| Phencyclidine | 500,000 | 0.00 % |
| Phenobarbital | 500,000 | 0.00 % |
| Propoxyphene | 100,000 | 0.00 % |
| Ranitidine | 500,000 | 0.00 % |
| Salicyluric acid | 500,000 | 0.00 % |
| Secobarbital | 500,000 | 0.00 % |
| 11-nor- THC-COOH | 500,000 | 0.00 % |
| Valproic Acid | 500,000 | 0.00 % |
| Verapamil | 500,000 | 0.00 % |
k191638 - Page 7 of 9
{7}
4. Assay Reportable Range:
Not applicable.
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
Two levels of calibrators (0 and 150 ng/mL) are available for use with the Pointe Scientific Cocaine Metabolite Enzyme Immunoassay. A commercially available benzoylecgonine standard solution from Cerilliant Analytical Reference Standards is used that is traceable to NIST standard.
6. Detection Limit:
Not applicable.
7. Assay Cut-Off:
The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay has a cutoff of 150 ng/mL benzoylecgonine.
## B Comparison Studies:
1. Method Comparison with Predicate Device:
Two methods comparison studies were conducted, one on the BS-480 Chemistry Analyzer and one on the BS-800M Chemistry Analyzer. 114 unaltered clinical urine remnant samples were evaluated over 3 nonconsecutive days by the Pointe Scientific Cocaine Metabolite Enzyme Immunoassay and compared to LC/MS. Results. The data is summarized below for each analyzer.
BS-480 Chemistry Analyzer:
| Candidate Device Results | Negative | < 75 ng/mL by LC/MS | 75-150 ng/mL by LC/MS | 150-225 ng/mL by LC/MS | >225 ng/mL by LC/MS |
| --- | --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 1 | 4 | 36 |
| Negative | 56 | 8 | 4 | 5 | 0 |
BA-800M Chemistry Analyzer:
| Candidate Device Results | Negative | < 75 ng/mL by LC/MS | 75-150 ng/mL by LC/MS | 150-225 ng/mL by LC/MS | >225 ng/mL by LC/MS |
| --- | --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 1 | 6 | 36 |
| Negative | 56 | 8 | 4 | 3 | 0 |
2. Matrix Comparison:
k191638 - Page 8 of 9
{8}
Not applicable.
## C Clinical Studies:
1. **Clinical Sensitivity:**
Not applicable.
2. **Clinical Specificity:**
Not applicable.
3. **Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):**
Not applicable.
## D Clinical Cut-Off:
Not applicable.
## E Expected Values/Reference Range:
Not applicable.
## VII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
## VIII Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
k191638 - Page 9 of 9
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the Tutorial button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only software-only devices, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (software-only devices), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.
